Impact of COVID-19 on Phase I Clinical Activities
Life sciences companies challenged by need to minimize health risks without sacrificing data quality during pandemic.
Diversity in Clinical Trials Gains Ground Amidst COVID
FDA emphasizes importance of inclusion in trials.
Biden Pandemic Plan Highlights R&D Support
President unveils lengthy program for combatting COVID-19 immediately following inauguration.
Applied Clinical Trials, January/February 2021 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials January/February 2021 issue in an interactive PDF format.
New Alliance Seeks to Bring Increased Accessibility to Trials
Co-conveners of the newly formed Decentralized Trials & Research Alliance, Amir Kalali, MD and Craig Lipset discuss the alliance as well as how COVID-19 has impacted the industry.
Improving Drug Development for Rare Patients Post-COVID
Non-profit biotech organization Cure Rare Disease utilizes collaboration amidst COVID-19 pandemic to catalyze speed of therapeutic research.
2021 Promises for Clinical Trials
A look forward to 2021 for the clinical trials industry.
Sharpening the Focus on Patient-Centricity as Pandemic Continues
Hybrid studies, patient-centric tools, and collaborations create big changes for clinical trials and stakeholders during COVID-19.
News Notes (January & February)
A compilation of recent notable news developments that pertain to the clinical trials industry.
EMA’s Cooke Reviews European Cancer Prospects
Cancer still a primary focus of EMA in light of COVID and vaccine development.
Characterizing Clinical Data Management Challenges and Their Impact
2020 Tufts CSDD – IBM Watson Health benchmarking study highlights need for new functionality from EDC solutions and providers.
Shifting Expectations for Clinical Development
COVID-19 speeds up clinical research and creates new advancements within industry.
2 Commerce Drive Cranbury, NJ 08512